Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495248 | 1.00 | NUDT1 (0.39) | NUDT1CSNK2A1ADORA3ADORA2AADORA1 | |
| SCHEMBL6474576 | 0.83 | NUDT1 (0.39) | NUDT1CSNK2A1ADORA3ADORA2AADORA1 | |
| SCHEMBL5376356 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL10617985 | 0.74 | PNP (0.48) | NUDT1CSNK2A1MAPT | |
| SCHEMBL31715124 | 0.71 | — | — | |
| SCHEMBL29495178 | 0.68 | — | — | |
| SCHEMBL1716322 | 0.66 | PNP (0.54) | MAPT | |
| SCHEMBL7228428 | 0.66 | ADORA3 (0.53) | ADORA3ADORA2AADORA1XDHMAPT | |
| SCHEMBL12592351 | 0.65 | CSNK2A1 (0.38) | CSNK2A1ADORA3 | |
| SCHEMBL37384 | 0.65 | DPP4 (0.66) | ADORA3XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-20260001880-A1 | Bicyclic DGK Inhibitors | INCYTE CORPORATION | 2026-01-01 | — | — | US | disclosed |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-26 | — | — | US | disclosed |
| US-20250186450-A1 | COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS | INCYTE CORPORATION | 2025-06-12 | — | — | US | disclosed |
| WO-2025122545-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025122695-A1 | COMBINATION THERAPY COMPRISING DGK INHIBITORS AND PD-1/PD-L1 INHIBITORS | INCYTE CORPORATION (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250179083-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2025-06-05 | — | — | US | disclosed |
| EP-4536362-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | Incyte Corporation (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025043151-A2 | BICYCLIC DGK INHIBITORS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20250066363-A1 | Bicyclic DGK Inhibitors | INCYTE CORPORATION | 2025-02-27 | — | — | US | disclosed |
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-04 | — | — | US | disclosed |
| WO-2021021986-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | RIBON THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-02-15 | — | — | US | disclosed |
| EP-2840083-B1 | NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-09-13 | — | — | EP | disclosed |
| US-9585889-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2017-03-07 | — | — | US | disclosed |
| CN-104284895-B | Nitrogenous dicyclic aromatic heterocyclic compounds | 安斯泰来制药株式会社 | 2016-08-31 | — | — | CN | disclosed |
| US-20160228442-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-9328118-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2840083-A1 | NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2015-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | NUDT1 472/4885CSNK2A1 3030/4885ADORA3 1866/4885 |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | NUDT1 472/4885CSNK2A1 3030/4885ADORA3 1866/4885 |
| US-20250066363-A1 | Bicyclic DGK Inhibitors | DGKA, DGKG, DGKK | NUDT1 1883/4885CSNK2A1 1576/4885ADORA3 3569/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | NUDT1 2412/4885CSNK2A1 1563/4885ADORA3 1048/4885 |
| US-20250186450-A1 | COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS | DGKG, DCK, DGKA | NUDT1 2795/4885CSNK2A1 1432/4885ADORA3 4477/4885 |
| US-20250179083-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | NUDT1 1754/4885CSNK2A1 1196/4885ADORA3 2835/4885 |
| US-20260001880-A1 | Bicyclic DGK Inhibitors | DGKA, DGKG, DGKZ | NUDT1 2795/4885CSNK2A1 367/4885ADORA3 1690/4885 |
| US-20160228442-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | CTSS, CTSV, CTSB | NUDT1 527/4885CSNK2A1 3801/4885ADORA3 1480/4885 |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | TTK, HDAC1, HDAC6 | NUDT1 3078/4885CSNK2A1 38/4885ADORA3 4624/4885 |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | CTSS, CTSV, CTSB | NUDT1 430/4885CSNK2A1 3676/4885ADORA3 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.